In silico and in vitro analysis of genetic variants of the equine CYP3A94, CYP3A95 and CYP3A97 isoenzymes.

The research study focuses on the genetic variations found in specific enzymes, namely the equine CYP3A94, CYP3A95, and CYP3A97, which are typically involved in drug metabolism in horses. The study applied in silico (computer simulation) and in vitro (experimental) methods to identify and characterize these genetic variants.

Methodology

• The researchers sequenced the genomes of 81 horses to find genetic variations in the CYP3A94, CYP3A95, and CYP3A97 enzymes. They focused on the most common variants.
• To understand the structural modifications these variations might cause, they created 3D-structure models using homology modeling. This computational method predicts a protein’s structure based on already identified proteins with similar amino acid sequences.
• To verify how these variations might alter enzyme function, the researchers tested enzyme kinetics using testosterone as a substrate, a chemical reaction’s ingredient. They studied how well the enzyme could metabolize the testosterone.

Findings

• The study identified twenty genetic variants, with five missense variants showing a high frequency. These missense variants are a type of mutation where a single nucleotide change results in a codon that specifies a different amino acid. This change can affect protein function.
• One splice-site variant, which could produce a cut-off protein, was present in 50% of the horses studied. Splice site variations can influence how genetic information is read, potentially producing non-working proteins or different versions of proteins.
• Two missense variants were positioned on a significant area for substrate interactions in the similar human enzyme CYP3A4, indicating that these variations might have similar impacts on horse enzymes.
• The ability of the enzymes to hydroxylate testosterone (add a hydroxyl group, altering the hormone’s function) was reduced in two of the variants. This decrease suggests that these mutations could reduce the enzyme’s general effectiveness.
• The antifungal drug Ketoconazole influenced hydroxylation differently among the five studied variants, pointing to different drug interactions depending on the genetic makeup of the horse’s CYP3A enzymes.

Importance

This study contributes valuable information about the functionality of the equine CYP3A proteins. These insights can aid in predicting certain horses’ reactions to medication based on their genetic variations, potentially leading to improved individualized drug therapies. Furthermore, it underlines the significance of combining in vitro and in silico methods for a thorough understanding of genetic variants’ effects.